Follow-Up After Treatment Lacking for Younger Cancer Survivors

Share this content:
Many younger patients are not well informed regarding long-term risks and cancer therapy side effects.
Many younger patients are not well informed regarding long-term risks and cancer therapy side effects.

(HealthDay News) -- Many adolescent and young adult (AYA) cancer survivors are not receiving adequate follow-up care, according to a study presented at the American Society of Clinical Oncology's annual Cancer Survivorship Symposium, held from Feb. 16 to 17 in Orlando, Fla.

Lynda M. Beaupin, M.D., from the Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues compared trends in follow-up among AYA cancer survivors. Data were obtained for two sets of survivors: 852 patients diagnosed between 2010 and 2014 (cohort A) and 783 patients diagnosed between 2005 and 2009 (cohort B).

The researchers found that 2,367 AYAs were diagnosed between 2000 and 2015. Since 2015, 37 percent had no follow-up visit, with no significant variation seen across disease types. Overall, 33 and 48 percent of cohorts A and B, respectively, were not seen in 2016, regardless of insurance coverage. There was no correlation between follow-up status and disease type or insurance status.

"Many adolescents and young adults are unaware of what their long-term risks are after they have finished their cancer treatment," Beaupin said in a statement. "Doctors and other health care providers need to be more diligent in letting these patients know about future potential side-effects and health risks that could occur based on certain aspects of their cancer treatment."

One author disclosed financial ties to Spectrum Pharmaceuticals.

Press Release
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs